Hence, we propose that recently discovered IP-specific inhibitors49, 50 could have substantial efficacy for treatment of IPhigh AMLs (mostly AML with an M5 phenotype and/or MLL rearrangements), and perhaps other types of IPhigh cancers, particularly those of hematopoietic origin (Supplementary Fig. S2). The gene discussed is KMT2A; the disease is acute myeloid leukemia.